Home/Healthcare/Drug Pipeline/ARBs Market

ARBs Market Report - Strategic Insights and Forecasts (2026-2031)

$3,950
Single User License
Report OverviewTable of ContentsCustomize Report

Request Customization

Tell us your specific requirements and we will customize this report for you.

📞

Your data is secure. We do not share information with any third party.

ARBs Market Report

Report IDKSI-008738
PublishedJun 2026
Pages159
FormatPDF, Excel, PPT, Dashboard

Need Assistance?

Our research team is available to answer your questions.

Contact Us
Frequently Asked Questions

The report highlights the rising global burden of hypertension and cardiovascular disease, alongside increasing prevalence of chronic kidney disease and Type 2 diabetes, as major market drivers. Additionally, strong guideline support from organizations like the American Heart Association and European Society of Cardiology, coupled with ARBs' favorable tolerability profile compared to ACE inhibitors, will sustain market expansion through 2031.

The market analysis identifies Losartan, Valsartan, Telmisartan, Olmesartan, Candesartan, and Irbesartan as the leading marketed molecules within the cardiovascular ARBs market. These key molecules are extensively prescribed for a broad range of indications, supporting their strong global utilization.

Global epidemiological trends such as the increasing prevalence of hypertension, diabetes, obesity, and chronic kidney disease significantly expand the addressable patient population for ARBs. This sustained growth in chronic disease burdens directly contributes to a rising demand for ARBs, given their efficacy in blood pressure reduction and long-term cardiovascular and renal protection.

ARBs demonstrate widespread adoption due to their efficacy comparable to ACE inhibitors, combined with improved tolerability, particularly a lower incidence of cough and angioedema. Furthermore, the extensive global availability of low-cost generics ensures broad patient access and robust competitive positioning within the market.

According to the report, ARBs are primarily prescribed for hypertension, heart failure, diabetic nephropathy, chronic kidney disease, and cardiovascular risk reduction. Their mechanism of action provides benefits across these critical areas, establishing them as cornerstone therapies in cardiovascular medicine.

The strategic outlook for ARBs is positive, with sustained strong global utilization projected through 2031. This is driven by their broad clinical applicability, favorable safety profile, inclusion in international treatment guidelines, and their role in providing effective blood pressure reduction and long-term cardiovascular protection for high-risk patients.

Need data specifically for your business?Request Custom Research →

Trusted by the world's leading organizations

Weber Shandwick
veolia
Tri
tls
TeamViewer
GE Healthcare
Intel
Proctor and Gamble
ABB
Elkem
Defense Logistics Agency
Amazon